Brivaracetam

CHEMBL607400 Phase 4 معتمد Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

212.3 g/mol

LogP

1.0

Phase

4

An anticonvulsant medication used as adjunctive therapy in adults and children with focal-onset seizures. It binds to a specific protein in nerve terminals called SV2A to modulate neurotransmitter release and reduce excessive neuronal firing. It has a rapid onset of action and is available in both oral and intravenous formulations.

الوزن الجزيئي

212,2900 g/mol

LogP

1,00

TPSA

63,40 Å²

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

Epilepsy

آلية العمل

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC[C@@H]1CC(=O)N([C@@H](CC)C(N)=O)C1

InChI

InChI=1S/C11H20N2O2/c1-3-5-8-6-10(14)13(7-8)9(4-2)11(12)15/h8-9H,3-7H2,1-2H3,(H2,12,15)/t8-,9+/m1/s1

Molecular Formula

C11H20N2O2

HBD / HBA

1 / 2

الروابط القابلة للدوران

5

الذرات الثقيلة

15

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

An anticonvulsant medication used as adjunctive therapy in adults and children with focal-onset seizures. It binds to a specific protein in nerve terminals called SV2A to modulate neurotransmitter release and reduce excessive neuronal firing. It has a rapid onset of action and is available in both oral and intravenous formulations.

Modulates neuronal excitability through one or more mechanisms including blockade of voltage-gated sodium channels, enhancement of GABAergic inhibition, or modulation of calcium channels. This reduces the frequency and severity of seizure activity.

Yes, Brivaracetam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL607400. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9837243. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Brivaracetam على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C11H20N2O2
المرادفات: 2

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.